

# 13-Valent Pneumococcal Conjugate Vaccine

Nancy M. Bennett, MD, MS  
Pneumococcal Vaccines Work Group Chair  
Advisory Committee on Immunization Practices  
October 23, 2013



# Pneumococcal Vaccines Work Group

## ACIP members

Nancy Bennett (Chair)

Arthur Reingold

Jeffrey Duchin

Allison Kempe

Lorry Rubin

## Ex Officio members

Lucia Lee (FDA)

Tina Mongeau (FDA)

## Designated Federal Officer (CDC/NCIRD)

Tamara Pilishvili

## Liaison representatives and consultants

Rick Zimmerman (AAFP)

William Schaffner (NFID)

Caroline Quach (NACI)

Mark Sawyer (AAP, PIDS)

Jane Zucker (AIM)

Monica Farley (VA)

Kathy Neuzil (IDSA)

Anthony Brenneman (AAPA)

Sandra Fryhofer (ACP, AMA)

# **Pneumococcal Vaccines Work Group: Terms of Reference**

- Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines
- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence
- Revise or update recommendations for pneumococcal vaccine use, as needed

# Focus of today's session

- 13-valent pneumococcal conjugate vaccine (PCV13)
- Routine infant immunization schedule for PCV13

# Pneumococcal WG activities 2010-2013

Routine recs for infants and children; permissive recs for 6-18 years olds with IC

Feb 2010

Deferred routine recs for adults pending results of CAPITA and indirect effects

Dec 2011

Recommendations for adults with IC

Feb 2012

Jun 2012

Recommendations for 6-18 years olds with IC

Jan 2013

Feb 2013

PCV13 licensed (replaced PCV7)

PCV13 licensed for adults  $\geq 50$  years old

PCV13 licensed for children 6-17 years old

IC = with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants

# Context for today's session

- PCVs used in the U.S. for past 12 years on 4-dose schedule (at 2, 4, 6, and 12 through 15 months of age)
- PCV7 use led to reductions in otitis media in children and invasive pneumococcal disease (IPD) and pneumonia in children and adults
- Evidence emerging supporting 3-dose PCV schedule
  - RCTs evaluating efficacy and immunogenicity
  - Observational studies evaluating impact (at least 34 high or upper-middle income countries have introduced PCV13 or PCV10 with 3 doses)

# Objective for today's session

- Information only session; no specific recommendations will be presented
- Review evidence and discuss considerations for including a 3-dose PCV13 schedule for infants
- Questions for the committee
  - Is the evidence adequate to consider including a 3-dose PCV13 schedule for infants?
  - If not, what additional data or information would be required?

# Today's presentations

<b>Update on PCV13 direct and indirect effects &amp; vaccine effectiveness</b>	<b>Matt Moore</b>
<b>Discussion/Q&amp;A</b>	
<b>Reduced dose schedules of PCV13 for children: review of evidence</b>	<b>Tamara Pilishvili</b>
<b>Discussion/Q&amp;A</b>	
<b>Cost-effectiveness of PCV13 reduced dose schedules</b>	<b>Charles Stoecker</b>
<b>Discussion/Q&amp;A</b>	